The table below shows Celldex Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$210.94M
-$157.78M
-$107.29M
-$103.73M
-$60.91M
-$40.40M
Capital expenditure
$2.71M
$1.92M
$1.82M
$1.83M
$1.25M
$1.55M
Investing cash flow
$209.07M
-$290.13M
-$105.78M
$89.94M
-$216.16M
-$98.22M
Dividends paid
-
-
-
-
CLDX operating cash flow (10-K history)
Celldex Therapeutics, Inc. reported operating cash flow of -$210.94M for fiscal year 2025. That is down 33.7% from -$157.78M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$113.04M (FY 2016) to -$210.94M. Figures come from the company's audited annual reports as filed with the SEC.
